<DOC>
	<DOCNO>NCT00993382</DOCNO>
	<brief_summary>The Primary objective ass efficacy Celivarone prevention Implantable Cardioverter Defibrillator ( ICD ) intervention death . Secondary objective : - To assess tolerability safety different dose regimen Celivarone select population . - To document Celivarone plasma level study .</brief_summary>
	<brief_title>Dose Ranging Study Celivarone With Amiodarone Calibrator Prevention Implantable Cardioverter Defibrillator ( ICD ) Interventions Death</brief_title>
	<detailed_description>The study include one week screening period , follow treatment period range 6 19 month . The treatment continue End Treatment visit schedule 10-15 day prior common Scheduled Study End Date ( SSED ) . The SSED define 190 day last patient randomization date . The expected recruitment duration 14 month thus total duration study 20 month . Visits plan performed baseline , 5 day , 14 day , every month 6 month , every three month 6 month end study .</detailed_description>
	<mesh_term>Amiodarone</mesh_term>
	<criteria>Inclusion criterion : Implantable Cardioverter Defibrillator ( ICD ) patient Left Ventricular Ejection Fraction ( LVEF ) 40 % less AND one follow criterion : least one ICD therapy Ventricular Tachycardia ( VT ) OR Ventricular Fibrillation ( VF ) previous month OR ICD implantation previous month document VT/VF Exclusion criterion : Patients either sex age 21 year ( age legal consent country ) , Women childbearing potential without adequate birth control pregnant breastfeed woman Patients know ICD lead problem ( lead dislodgement ) ICD without follow characteristic : data log function cumulative counting device intervention ( shock antitachycardia pace [ ATP ] ) electrogram storage capability ventricular demand pacing . Recent unstable angina pectoris myocardial infarction ( &lt; 4 week ) , History torsades de pointes , Genetic channelopathies include congenital long QT syndrome , WolffParkinsonWhite syndrome , Patients unstable hemodynamic condition acute pulmonary edema within 12 hour prior start study medication ; cardiogenic shock ; treatment intravenous pressor agent ; patient respirator ; congestive heart failure stage New York Heart Association ( NYHA ) IV within last 4 week ; uncorrected , hemodynamically significant primary obstructive valvular disease ; hemodynamically significant obstructive cardiomyopathy ; cardiac operation revascularization procedure within 4 week precede randomization , Incessant sustain VT/VF ( VT/VF recur promptly despite termination attempt ) three day precede randomization . Patients inappropriate ( triggered VT VF ) shock month precede randomization . Clinically relevant haematologic , hepatobiliary ( ALT , AST &gt; 3 time upper limit normal randomization ) , gastrointestinal , renal ( serum creatinine &gt; 221 Âµmol/l ( 2.5 mg/dl ) randomization ) , pulmonary , endocrinologic psychiatric disease . Patients treat oral amiodarone ( 20 tablet 2 month precede randomization ) The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>